The scientific efforts led by Salvemini, who is professor of pharmacological and physiological sciences at SLU, demonstrated that turning on a receptor in the brain and spinal cord counteracts chronic nerve pain in male and female rodents. Activating the A3 receptor—either by its native chemical stimulator, the small molecule adenosine, or by powerful synthetic small molecule drugs invented at the NIH—prevents or reverses pain that develops slowly from nerve damage without causing analgesic tolerance or intrinsic reward (unlike opioids).

Pain is an enormous problem. As an unmet medical need, pain causes suffering and comes with a multi-billion dollar societal cost. Current treatments are problematic because they cause intolerable side effects, diminish quality of life and do not sufficiently quell pain.

The most successful pharmacological approaches for the treatment of chronic pain rely on certain "pathways": circuits involving opioid, adrenergic, and calcium channels.

For the past decade, scientists have tried to take advantage of these known pathways—the series of interactions between molecular-level components that lead to pain. While adenosine had shown potential for pain-killing in humans, researchers had not yet successfully leveraged this particular pain pathway because the targeted receptors engaged many side effects.

In this research, Salvemini and colleagues have demonstrated that activation of the A3 adenosine receptor subtype is key in mediating the pain relieving effects of adenosine.

"It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain," Salvemini said. "Our findings suggest that this goal may be achieved by focusing future work on the A3AR pathway, in particular, as its activation provides robust pain reduction across several types of pain."

Researchers are excited to note that A3AR agonists are already in advanced clinical trials as anti-inflammatory and anticancer agents and show good safety profiles. "These studies suggest that A3AR activation by highly selective small molecular weight A3AR agonists such as MRS5698 activates a pain-reducing pathway supporting the idea that we could develop A3AR agonists as possible new therapeutics to treat chronic pain," Salvemini said.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Why the New RomCom ‘MERV’ Can Bring You Joy This Christmas

How the 'Heavens Declare the Glory of God': What One Man's Research Has Revealed about The Star of Bethlehem

Over 50 Tren de Aragua Gang Members Imported Under Democrats Indicted in Nebraska in Massive Nationwide ATM Jackpotting Scheme

205 Child Victims Located and Rescued in DOJ Sex Exploitation Op

Trump Admin Pausing All Off Shore Wind Project Construction Due To National Security Concerns

Trump Grants Federal Workers Two Additional Christmas Holidays

America Fest 2025: Erika Kirk Endorses 'My Husband's Friend' JD Vance for President

Brent Bozell Confirmed as US Ambassador to South Africa

Jury Quickly Convicts Judge Who Helped Illegal Migrant Escape ICE

Feds Estimate Somali-Linked Fraud in Walz's Minnesota Could Top $9 Billion

Trump SUSPENDS 'Green Card Lottery' after Program Let Brown University–MIT Shooting Suspect Enter the US

Brown, MIT Shooter Found Dead for Days in NH Storage Unit; Motive Still a Mystery

House Passes Bill to Criminalize Transgender Mutilation of Children

November Inflation Falls to 2.7%, Lower than Expected: 'This Is Good News for Wall Street; It’s Good News for Main Street'

MOVIEGUIDE's Review of the New Animated Film: DAVID

Massachusetts Drops Controversial Gender Ideology Mandate for Licensing Foster Care Parents

Nearly 40% of Women Suffer Severe Grief for Years after Abortion, Miscarriage: Study

Former Pfizer Vice President: COVID Shots Were 'Designed to Cause Injury,' Reduce Fertility

Dutch Sheets Shares a Warning from the US National Counterterrorism Center

Venezuela: Trump's Pressure Campaign and Maduro's Fury